Treatment of candidemia with echinocandins: Data on hospital resource use from a real world setting

Journal of Medical Economics

Volumn 15, Issue 6, 2012, Pages 1130-1138

  Wade, Rolin L ^a   Chaudhari, Paresh ^b   Campbell, Rebecca S ^a   Hays, Harlen D ^a   Nathanson, Brian H ^d   Yi, Jing ^c   Horn, David ^d  

^a CERNER CORPORATION   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c OptiStatim LLC   (United States)

^d David Horn LLC   (United States)

Author keywords

Antifungal; Candidemia; Echinocandin; Fluconazole; Resource utilization; Treatment

Indexed keywords

ECHINOCANDIN; FLUCONAZOLE;

ADULT; ARTICLE; CANDIDA; CANDIDEMIA; COMBINATION CHEMOTHERAPY; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; TREATMENT OUTCOME;

AGED; ANTIFUNGAL AGENTS; CANDIDEMIA; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HOSPITAL CHARGES; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84869746815     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.708690     Document Type: Article

References (17)

1. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Inf Dis 2005;41:1232-9
2. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009;48:1695-703
3. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35
4. Reboli AC, Rotstein C, Kett DH, et al. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. Pharmacoeconomics 2011; 29:705-17
5. Cunha BA. Principles of antibiotic formulary selection for P&T committees. P&T 2003;28:662-5
6. Wade R, Chaudhari P, Campbell R, et al. Initial treatment patterns and antifungal switching in hospitalized patients with candidemia. Infectious Diseases Society of America 49th Annual Meeting. Boston, MA, October 22, 2011
7. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10
8. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics 2000;56:645-6
9. Rogers W. Regression standard errors in clustered samples. Stata Technical Bulletin 1993;13:19-23
10. Austin PC, Tu J. Bootstrap methods for developing predictive models. Am Statistician 2004;58:131-7
11. Craver CW, Tarallo M, Roberts CS, et al. Cost and resource utilization associated with fluconazole as first-line therapy for invasive candidiasis: a retrospective database analysis. Clin Ther 2010;32:2467-77
12. Wilke M. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res 2011;16:180-6
13. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48:1366-77
14. Arnold HM, Micek ST, Shorr AF, et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010;30:361-8
15. Zilberberg MD, Kollef MH, Arnold H, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010;10:150
16. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31
17. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5